4-(3-(piperidin-1-yl)propoxy)benzoyl chloride | 752202-08-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(3-(piperidin-1-yl)propoxy)benzoyl chloride
• 英文别名: 4-[3-(1-piperidinyl)propyloxy]benzoyl chloride；4-(3-Piperidin-1-ylpropoxy)benzoyl chloride
• CAS: 752202-08-7
• 化学式: C₁₅H₂₀ClNO₂
• 分子量: 281.782
• InChiKey: YGBSITZIDOMYLV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(3-(piperidin-1-yl)propoxy)benzoyl chloride 在 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 三乙胺 作用下， 以 二氯甲烷 、 氯仿 为溶剂， 反应 31.0h， 生成 2-[4-(3-Piperidin-1-ylpropoxy)phenyl]-4,5-dihydro-1,3-oxazole
  参考文献：
  名称：

  Novel and highly potent histamine H3 receptor ligands. Part 1: withdrawing of hERG activity

  摘要：

  Pre-clinical investigation of some aryl-piperidinyl ether histamine H3 receptor antagonists revealed a strong hERG binding. To overcome this issue, we have developed a QSAR model specially dedicated to H3 receptor ligands. This model was designed to be directly applicable in medicinal chemistry with no need of molecular modeling. The resulting recursive partitioning trees are robust (80-85% accuracy), but also simple and comprehensible. A novel promising lead emerged from our work and the structure-activity relationships are presented. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.07.006
• 作为产物：
  描述：

  4-(3-(哌啶-1-基)丙氧基)苯甲酸 在 氯化亚砜 作用下， 反应 15.0h， 生成 4-(3-(piperidin-1-yl)propoxy)benzoyl chloride
  参考文献：
  名称：

  Novel and highly potent histamine H3 receptor ligands. Part 1: withdrawing of hERG activity

  摘要：

  Pre-clinical investigation of some aryl-piperidinyl ether histamine H3 receptor antagonists revealed a strong hERG binding. To overcome this issue, we have developed a QSAR model specially dedicated to H3 receptor ligands. This model was designed to be directly applicable in medicinal chemistry with no need of molecular modeling. The resulting recursive partitioning trees are robust (80-85% accuracy), but also simple and comprehensible. A novel promising lead emerged from our work and the structure-activity relationships are presented. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.07.006

文献信息

• [EN] BICYCLIC BENZAMIDE COMPOUNDS AS HISTAMINE H3 RECEPTOR LIGAND USEFUL IN THE TREATMENT OF NEUROLOGICAL DISEASES<br/>[FR] COMPOSES BENZAMIDE BICYCLIQUES TENANT LIEU DE LIGANDS DU RECEPTEUR H3 DE L'HISTAMINE, UTILES DANS LE TRAITEMENT DES MALADIES NEUROLOGIQUES
  申请人：GLAXO GROUP LTD

  公开号：WO2004037788A1

  公开（公告）日：2004-05-06

  The present invention relates to novel bicyclic benzamide derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.

  本发明涉及具有药理活性的新型双环苯甲酰胺衍生物，其制备方法，含有它们的组合物以及它们在治疗神经系统和精神疾病中的应用。
• [EN] ARYLOXYALKYLAMINE DERIVATES AS H3 RECEPTOR LIGANDS<br/>[FR] DERIVES D'ARYLOXYALKYLAMINE TELS QUE DES LIGANDS DU RECEPTEUR H3
  申请人：GLAXO GROUP LTD

  公开号：WO2004037800A1

  公开（公告）日：2004-05-06

  The present invention relates to novel benzyloxy derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.

  本发明涉及具有药理活性的新型苄氧基衍生物，其制备方法，含有它们的组合物以及它们在治疗神经系统和精神疾病中的用途。
• [EN] MULTIFACETED APPROACH TO NOVEL INTERLEUKIN-6 INHIBITORS<br/>[FR] APPROCHE À FACETTES MULTIPLES POUR DE NOUVEAUX INHIBITEURS DE L'INTERLEUKINE-6
  申请人：UNIV FLORIDA

  公开号：WO2022226133A1

  公开（公告）日：2022-10-27

  The instant disclosure describes compounds having IL-6 modulating activity, pharmaceutical compositions and kits thereof, and methods of treating diseases, disorders or symptoms thereof mediated by IL-6.

  本公开介绍了具有 IL-6 调节活性的化合物、其药物组合物和试剂盒，以及治疗由 IL-6 介导的疾病、失调或症状的方法。
• Bicyclic bradykinin receptor antagonists
  申请人：ELI LILLY AND COMPANY

  公开号：EP0707852A2

  公开（公告）日：1996-04-24

  This invention also provides methods for treating or preventing conditions associated with an excess of bradykinins which methods comprise administration of one or more of the substituted indoles, benzofurans, or benzothiophenes described in this invention.

  本发明还提供了治疗或预防与缓激肽过量有关的疾病的方法，这些方法包括施用一种或多种本发明所述的取代吲哚、苯并呋喃或苯并噻吩。
• Compositions for treating resistant tumors
  申请人：ELI LILLY AND COMPANY

  公开号：EP0709090A2

  公开（公告）日：1996-05-01

  The present invention provides methods for reversing multidrug resistance in a resistant neoplasm by treating a mammal in need of said treatment with a substituted indole, benzofuran, benzothiophene, naphthalene, or dihydronaphthalene. This invention also provides methods for treating neoplasms in a mammal which comprises administering to a mammal in need of this treatment a substituted indole, benzofuran, benzothiophene, naphthalene, or dihydronaphthalene in combination with an oncolytic agent.

  本发明提供了通过用取代的吲哚、苯并呋喃、苯并噻吩、萘或二氢萘处理需要所述处理的哺乳动物来逆转耐药性肿瘤的多药耐药性的方法。本发明还提供了治疗哺乳动物肿瘤的方法，其中包括向需要治疗的哺乳动物施用取代的吲哚、苯并呋喃、苯并噻吩、萘或二氢萘，并与溶瘤剂结合使用。